PNP Therapeutics, UAB and Southern Research Institute work abolishes otherwise unmanageable human cancers in preclinical rodent studies.
Clinicians will collaborate with local physicians, offering patients updated treatment recommendations and access to cutting-edge research.
Biomarkers could tailor preventative or therapeutic aspirin regimens by predicting patients’ response.